Previous 10 | Next 10 |
My plan for my investment in NantKwest ( NK ) was to build a conservative position in anticipation that the market will start to identify the prospective upside in the stock. Indeed, NantKwest still has a couple of years from a potential product launch. Still, I expect CEO and founder Dr. Soon...
Editor's note: Seeking Alpha is proud to welcome PylBio Investment as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Welcome to ou...
AbbVie ( ABBV ) had entered into a deal to acquire Allergan ( AGN ) for $63 billion, which would be $188 a share in cash and stock. This was a huge premium of 45% over the closing price of $129.57 on Monday, June 25, 2019. AbbVie's stock tanked on this news, closing lower by 16%. In my...
Bristol-Myers Squibb ( BMY ) started 2019 by announcing it would acquire Celgene ( CELG ). The combination will create what will be one of the broadest sets of drugs that are both approved and/or in a pipeline. The combination of these companies will likely have better than appreciated cash ...
Bristol-Myers Squibb Co. ( BMY ) disclosed that it needs to dispose of Celgene’s ( CELG ) Otezla to address US Federal Trade Commission ((FTC)) fears over the possibility of BMY/CELG dominating in the psoriasis space. As a result, the BMY/CELG merger finalization is expected to be pushe...
By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...
Merger activity went on a tear last week with twelve new deals announced and one pending deal closing. Deal Statistics: New Deals: The acquisition of Caesars Entertainment Corporation (CZR) by Eldorado Resorts (ERI) for $17.3 billion in a cash plus stock deal. Under the terms of...
AnaptysBio ( ANAB ) stock closed lower by 11% on Friday after a rival drug known as REGN3500 from Regeneron Pharmaceuticals ( REGN ) and its partner Sanofi ( SNY ), failed a mid-stage study in asthma . I believe that despite a rival failing with a similar drug, AnaptysBio's stock should...
AbbVie Inc. (ABBV) has reached a deal with Allergan (AGN) for about $188 per share in cash and stock. Allergan shareholders get $120 in cash and 17% of the combined company (the value of that is in flux, so take the numbers with a grain of salt). This implies there is still a very widespread o...
Mergers is the sign of a healthy stock market AbbVie (ABBV) is buying the long-suffering Allergan (AGN) for 63 billion bucks. Long-term readers might remember me making a strong case to go long on AGN because of the charts, and then Carl Icahn got involved, so we were able to escape with som...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...